Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of clinical features between suspected familial colorectal cancer type X and Lynch syndrome in Japanese patients with colorectal cancer: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum.
Yamaguchi T, Furukawa Y, Nakamura Y, Matsubara N, Ishikawa H, Arai M, Tomita N, Tamura K, Sugano K, Ishioka C, Yoshida T, Moriya Y, Ishida H, Watanabe T, Sugihara K; HNPCC Registry and Genetic Testing Project of the Japanese Society for Cancer of the Colon and Rectum. Yamaguchi T, et al. Among authors: ishioka c. Jpn J Clin Oncol. 2015 Feb;45(2):153-9. doi: 10.1093/jjco/hyu190. Epub 2014 Nov 17. Jpn J Clin Oncol. 2015. PMID: 25404568
[Familial breast cancer genes].
Chiba N, Ishioka C. Chiba N, et al. Among authors: ishioka c. Nihon Rinsho. 2007 Jun 28;65 Suppl 6:601-5. Nihon Rinsho. 2007. PMID: 17682216 Review. Japanese. No abstract available.
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, Mori T, Komine K, Iwama N, Kato S, Ishioka C. Soeda H, et al. Among authors: ishioka c. Int J Clin Oncol. 2013 Aug;18(4):670-7. doi: 10.1007/s10147-012-0422-8. Epub 2012 May 26. Int J Clin Oncol. 2013. PMID: 22638623
Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients.
Kato S, Andoh H, Gamoh M, Yamaguchi T, Murakawa Y, Shimodaira H, Takahashi S, Mori T, Ohori H, Maeda S, Suzuki T, Kato S, Akiyama S, Sasaki Y, Yoshioka T, Ishioka C; Tohoku Clinical Oncology Research and Education. Kato S, et al. Among authors: ishioka c. Oncology. 2012;83(2):101-7. doi: 10.1159/000339541. Epub 2012 Jul 9. Oncology. 2012. PMID: 22777333 Clinical Trial.
Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C. Soeda H, et al. Among authors: ishioka c. Oncology. 2014;87(1):7-20. doi: 10.1159/000360989. Epub 2014 Jun 24. Oncology. 2014. PMID: 24968756 Clinical Trial.
301 results